調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026

インフルエンザワクチンの世界市場：売上予測および研究開発展望

◆タイトル：Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026
◆商品コード：VGAIN6012612
◆調査・発行会社：visiongain
◆発行日：2016年1月
◆ページ数：139
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）

Single User（1名利用）	GBP1,799 ⇒換算￥269,850	見積依頼/購入/質問フォーム
Five User	GBP2,999 ⇒換算￥449,850	見積依頼/購入/質問フォーム
Site License（全社内共有可）	GBP4,999 ⇒換算￥749,850	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、インフルエンザワクチンの世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・インフルエンザワクチンの世界市場
　（市場規模予測、市場動向、市場の成長要因・阻害要因など）
・インフルエンザワクチンの世界市場：セグメント別分析
　（3価インフルエンザワクチン、4価インフルエンザワクチン）
・インフルエンザワクチンの世界市場：主要ワクチンの売上予測
・インフルエンザワクチンの世界市場：地域別市場分析、市場規模予測
・研究開発パイプライン分析
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Influenza Vaccines – Your 2016 Guide to Developments and Sales Potentials
Do you want to explore the future of vaccines against the influenza virus? If so, visiongain’s new report shows you trends, R&D, sales results, opportunities and revenue forecasts.

Avoid missing out. With our research and analysis you assess companies, technologies and products, benefiting your reputation for commercial insight.

Read on to explore the flu shots industry and see what revenue its market could generate in future.

Sales prospects of human flu preventions – our study shows you what is possible
Our new study gives revenue predictions at overall world, submarket, product and national levels. You gain discussions and expert opinion on vaccines protecting against influenza:
• Influenza vaccine revenues to 2026 – discover the overall potential of that market worldwide, seeing commercial opportunities and possibilities
• 2 submarkets’ revenues to 2026 – explore that industry’s segments at world level, finding the most lucrative and promising technologies and trends
• 6 revenue forecasts covering leading vaccine brands to 2026 – see how those anti-flu agents can compete and succeed, discovering their sales potentials
• 11 leading countries’ revenue forecasts to 2026 – investigate countries in the Americas, Europe and Asia, assessing prospects for influenza market expansion
• Analysis of leading companies and R&D pipelines for that preventive medicine – assess potentials of companies, seeing how they can compete and succeed
• Assessment of what stimulates and restrains that important healthcare market – analyse challenges, strengths and views, seeing how you can gain.

Forecasting of that world market, showing what is possible for those prophylactic medicines
In our 138 page report you receive 32 tables, 32 charts and an interview with a vaccine producer. Besides giving revenue predictions, our new analysis shows you recent results, business news, sales growth rates, market shares and R&D trends.

First our study gives revenue forecasts to 2026 for two influenza submarkets:
• Trivalent vaccines
• Quadrivalent vaccines.

With our report you investigate influenza vaccine development, manufacturing and selling. You also explore potential shifts in market shares from 2016 to 2026. See what leading companies do, assessing that industry’s potential.

Product forecasts – assess sales potentials of leading brands
Our new analysis also shows you predictions for leading flu vaccines, giving six revenue forecasts to 2026:
• Fluzone/Vaxigrip
• Afluria/Fluvax
• Fluarix/FluLaval
• FluMist/Fluenz
• Fluvirin/Flucelvax
• FluBlok.

With our investigation you assess business potentials for leading influenza vaccines. You also explore research and development. Discover what is possible from 2016, then, benefiting your influence and reputation for commercial insight.

National markets for influenza vaccine sales – what does the future hold?
Our study shows you prospects for influenza vaccine revenues in developed and developing countries. There see individual forecasts to 2026 for 11 countries:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (the EU5 group)
• Brazil, Russia, India and China (the BRIC group).

With our analysis you investigate countries with highest revenues, demand and potential sales growth. Explore progress, needs and opportunities, seeing how you can gain.

Forces affecting developers, producers and sellers of those healthcare products
Our report explains issues, trends, events and R&D from 2016, including these forces:
• Paediatric and adult influenza vaccines – present and future developments
• Advances in research and development, including vaccine delivery technology – assess innovations, progress and opportunities
• Deals in that industry, including the creation of Seqirus in July 2015
• Antigenic drift and shift – overcoming viral challenges to protect populations
• Seasonal influenza epidemics and pandemic outbreaks giving high demand.

Also explore the effects of these influences:
• Governments and international organisations’ roles in flu vaccination
• Supply and demand, including effects of healthcare providers and payers’ policies
• US healthcare reforms – benefits for vaccine sales
• Strengths, weaknesses, opportunities and threats, as well as social, technological, economic and political forces – examine what influences that industry
• Potential for universal flu vaccine to transform the market – see what is possible.

Worldwide revenues of influenza vaccines will reach $6.4 billion in 2018, our study predicts. Sales will rise from 2016 to 2026 as technological advances and rising demand give growth opportunities. With our analysis you see what the future holds and how you can benefit.

Influenza vaccines – who are the top companies?
From 2016, large pharmaceutical companies and other biopharma specialists can prosper in that important healthcare market. Discover how, seeing organisations’ potentials.

In particular our study explores these industry leaders:
• Sanofi Pasteur
• GSK
• Novartis
• AstraZeneca
• CSL and Seqirus
• Protein Sciences Corporation.

【レポートの目次】

1. Report Overview
1.1 Global Influenza Vaccine Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. Introduction to the World Influenza Vaccines Market
2.1 What is Influenza and How Serious is it to Health Worldwide?
2.2 What is the Social and Economic Burden?
2.3 The Influenza Virus
2.3.1 Antigenic Drift
2.3.2 Antigenic Shift
2.4 An Epidemic or a Pandemic Outbreak?
2.4.1 Seasonal Influenza Epidemic
2.4.2 Pandemic Influenza
2.5 Key Influencers of the Influenza Vaccine Market
2.5.1 Governments and International Organisations
2.5.1.1 The World Health Organization (WHO)
2.5.1.2 Governmental Influence
2.5.2 Leading Manufacturers
2.5.2.1 Sanofi Pasteur
2.5.2.2 GSK
2.5.2.3 Novartis
2.5.2.4 AstraZeneca

3. Influenza Vaccine World Market Outlook, 2016-2026
3.1 The World Influenza Market Performance 2014
3.1.1 Growing Elderly Population
3.1.2 Paediatric Influenza Vaccines – High Demand
3.1.3 Emerging Markets
3.2 The World Influenza Market Revenue Forecast, 2015-2026
3.3 The World Influenza Market: Industry Trends, 2016-2026
3.3.1 Demand Driven Trends
3.3.2 Supply
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy

4. Influenza Vaccine Submarkets: Prospects, 2016-2026
4.1 Trivalent Influenza Vaccines
4.1.1 Trivalent Vaccines: Revenue Forecast to 2026
4.2 Quadrivalent Vaccines
4.2.1 Quadrivalent Vaccines: Revenue Forecast to 2026

5. Leading Influenza Vaccines: Revenue Predictions, 2016-2026
5.1 Fluzone/Vaxigrip (IIV4) – Sales Forecasting and Discussion 2015-2026
5.2 Afluria/Fluvax (IIV3) – Sales Forecasting and Discussion 2015-2026
5.3 Fluarix/FluLaval – Sales Forecasting and Discussion 2015-2026
5.4 FluMist/Fluenz (LAIV4) – Sales Forecasting and Discussion 2015-2026
5.5 Fluvirin (IIV3) / Flucelvax (ccIIV3) – Sales Forecasting and Discussion 2015-2026
5.6 FluBlok (RIV3) – Sales Forecasting and Discussion 2015-2026
5.7 Other Vaccines: Sales Forecasting and Discussion 2015-2026

6. Influenza Vaccines in Leading Developed Markets, 2016-2026
6.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026
6.1.1 Influenza Vaccine: Leading Developed Markets
6.2 The US Vaccine Market: 2016-2026
6.2.1 The US Vaccine Market: 2015
6.2.2 The US Vaccine Market Forecast: 2015-2026
6.2.3 Obama Healthcare Reform – Benefits for Vaccine Sales
6.3 The Japanese Influenza Vaccine Market 2016-2026
6.3.1 The Japanese Vaccine Market: 2015
6.3.2 The Japanese Vaccine Market Forecast: 2015-2026
6.3.3 Filing the Vaccine Gap
6.4 The United Kingdom Influenza Vaccine Market 2016-2026
6.4.1 The UK Vaccine Market: 2015
6.4.2 The UK Vaccine Market: 2015-2026
6.5 The German Influenza Vaccine Market: 2016-2026
6.5.1 The German Vaccine Market: 2015
6.5.2 The German Vaccine Market Forecast: 2015-2026
6.6 The French Influenza Vaccine Market 2016-2026
6.6.1 The French Vaccine Market: 2015
6.6.2 The French Vaccine Market Forecast: 2015-2026
6.6.3 French Healthcare System – Events, Policies and Effects
6.7 The Italian Influenza Vaccine Market: 2016-2026
6.7.1 The Italian Vaccine Market: 2015
6.7.2 The Italian Vaccine Market Forecast: 2015-2026
6.7.3 Uncertain Foundation – Challenges in Public Healthcare
6.8 The Spanish Influenza Vaccine Market 2016-2026
6.8.1 The Spanish Vaccine Market: 2015
6.8.2 The Spanish Vaccine Market Forecast: 2015-2026
6.8.3 District Rules – Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2016-2026
7.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026
7.1.1 Influenza Vaccine: Leading Emerging National Markets
7.2 The Chinese Influenza Vaccine Market: 2016-2026
7.2.1 The Chinese Influenza Vaccine Market: 2015
7.2.2 The Chinese Influenza Vaccine Market Forecast: 2015-2026
7.2.3 High National Demand for Influenza Vaccines
7.3 The Indian Influenza Vaccine Market: 2016-2026
7.3.1 The Indian Vaccine Market: 2015
7.3.2 The Indian Influenza Vaccine Market Forecast: 2015-2026
7.3.3 Complications of Influenza Vaccines – How Much Progress Possible?
7.4 The Brazilian Influenza Vaccine Market: 2016-2026
7.4.1 The Brazilian Vaccine Market: 2015
7.4.2 The Brazilian Vaccine Market Forecast: 2015-2026
7.5 The Russian Vaccine Market: 2016-2026
7.5.1 The Russian Vaccine Market: 2015
7.5.2 The Russian Vaccine Market Forecast: 2015-2026
7.5.3 Power of the State

8. R&D Pipeline for Flu Vaccines
8.1 Seasonal Influenza Vaccines in Development
8.1.1 Sanofi Pasteur
8.1.1.1 FLUZONE Quadrivalent
8.1.1.2 VaxiGrip QIV IM Quadrivalent
8.1.2 bioCSL
8.1.2.1 Quadrivalent Paediatric Influenza Vaccine
8.1.3 Novartis
8.1.3.1 Cell Culture Quadrivalent Intramuscular Vaccine
8.1.3.2 Quadrivalent Paediatric Intramuscular Vaccine
8.1.3.3 Fluad Vaccine
8.1.3.4 Flucelvax Intramuscular Vaccine
8.1.4 Takeda Pharmaceuticals
8.1.4.1 TAK850 Influenza Vaccine
8.2 Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2016-2026
9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2016
9.1.1 Strengths
9.1.1.1 Ageing Population
9.1.1.2 Influenza Prevention is Crucial
9.1.1.3 Sales Growth in Emerging National Markets
9.1.1.4 Rising Awareness of the Disease
9.1.2 Weaknesses
9.1.2.1 Supply Chain Costs
9.1.2.2 Time Pressure
9.1.2.3 Barriers to Market Entry
9.1.3 Opportunities
9.1.3.1 Strong Research and Development Pipeline
9.1.3.2 Vaccine Delivery – Innovations and Opportunities for Improvements
9.1.3.3 Universal Flu Vaccine
9.1.3.4 Adult Vaccines – High Need
9.1.4 Threats
9.1.4.1 Productivity Gap
9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2016
9.2.1 Social Factors
9.2.1.1 Creating a Healthier Society
9.2.1.2 Public Fears of Side-Effects
9.2.2 Technological Forces
9.2.2.1 Advancements in Vaccine Technology
9.2.3 Economic Factors
9.2.3.1 Cost and Time Restraints
9.2.3.2 Emerging Markets Create Demand
9.2.4 Political Factors
9.2.4.1 Influence of Governments

10. Research Interview
10.1 Interview with BiondVax Pharmaceuticals, 2013
10.1.1 Progress of BiondVax’s Candidate Vaccine
10.1.2 Trialling the Vaccine as a Primer
10.1.3 Assays for Universal Vaccine Effectiveness
10.1.4 Key Differentiators for BiondVax’s Candidate

11. Conclusions
11.1 Prevention of Influenza by Use of Flu Shots Rises in Importance
11.2 Japan as a Rising Consumer in the World Influenza Vaccine Market
11.3 Brazil and India Show Robust Growth
11.4 Emergence of a Universal Flu Vaccine
11.5 The US to Retain its Dominance
11.6 Concluding Remarks

List of Tables
Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
Table 3.1 Overall World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.1 Influenza Vaccines Sub-Markets: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.2 The Trivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 4.3 The Quadrivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026
Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2014
Table 5.2 Fluzone/Vaxigrip: Revenue ($m), 2012-2014
Table 5.3 Fluzone/Vaxigrip: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.4 Afluria/Fluvax: Revenue ($m), 2013-2014
Table 5.5 Afluria/Fluvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.6 Fluarix/FluLaval: Revenue ($m), 2012-2014
Table 5.7 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.8 FluMist/Fluenz: Revenue ($m), 2012-2014
Table 5.9 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.10 Fluvirin/Flucelvax Revenue ($m), 2013-2014
Table 5.11 Fluvirin/Flucelvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.12 FluBlok Revenue ($m), 2013-2014
Table 5.13 FluBlok: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 5.14 Other Influenza Vaccines Forecast: ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026
Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026
Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026
Table 8.1 Seasonal Influenza Vaccines in Development, 2015
Table 8.2 Universal Influenza Vaccines in Development, 2015

List of Figures
Figure 1.1 Influenza Vaccines Market Segmentation
Figure 3.1 Influenza Vaccines Market Shares (%), 2014
Figure 3.2 Growth in the Uptake of Influenza Vaccine, 1990-2015
Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2014
Figure 3.4 Time of Last Influenza Shot by Age, 2015
Figure 3.5 Influenza Vaccines: Market Share by Geographical Segmentation, 2015
Figure 3.6 World Influenza Vaccines Market: Drivers and Restraints, 2016-2026
Figure 4.1 Influenza Vaccines: Main Submarket Segmentation (%), 2014
Figure 4.2 Influenza Vaccines: Submarkets Shift in Market Share (%), 2014-2026
Figure 5.1 Fluzone/Vaxigrip: Revenue Forecast ($m), 2015-2026
Figure 5.2 Afluria/Fluvax: Revenue Forecast ($m), 2015-2026
Figure 5.3 Fluarix/FluLaval: Revenue Forecast ($m), 2015-2026
Figure 5.4 FluMist/Fluenz: Revenue Forecast ($m), 2015-2026
Figure 5.5 Fluvirin/Flucelvax: Revenue Forecast ($m), 2015-2026
Figure 5.6 FluBlok: Revenue Forecast ($m), 2015-2026
Figure 5.7 Other Influenza Vaccines: Revenue Forecast ($m), 2015-2026
Figure 6.1 Influenza Vaccine Market Share (%): Leading National Markets, 2014
Figure 6.2 Developed National Markets: Drivers and Restraints, 2016-2026
Figure 6.3 The US Influenza Vaccine Revenue Forecast ($m), 2015-2026
Figure 6.4 The Japanese Influenza Vaccine Revenue Forecast ($m), 2015-2026
Figure 6.5 The UK Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 6.6 The German Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 6.7 The French Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 6.8 The Italian Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 6.9 The Spanish Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 7.1 Emerging National Markets: Drivers and Restraints, 2016-2026
Figure 7.2 The Chinese Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 7.3 The Indian Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 7.4 The Brazilian Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 7.5 The Russian Influenza Vaccines Revenue Forecast ($m), 2015-2026
Figure 9.1 SWOT Analysis of the Influenza Vaccines Market, 2016
Figure 9.2 STEP Analysis of the Influenza Vaccines Market, 2016

【レポートのキーワード】

インフルエンザワクチン、売上予測、3価インフルエンザワクチン、4価インフルエンザワクチン、インフルエンザワクチン研究開発

★調査レポート[インフルエンザワクチンの世界市場：売上予測および研究開発展望] ( Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026 / VGAIN6012612) 販売に関する免責事項

[インフルエンザワクチンの世界市場：売上予測および研究開発展望] ( Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026 / VGAIN6012612) についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆